LifeSemantics‘s Canofy MD SCAI, an AI solution that detects skin cancer, has received approval from Korea’s Ministry of Food and Drug Safety, according to the Korean digital health company.
Canofy MD SCAI employs image processing technology based on convolutional neural networks to refine the classification of malignant and benign tumors. It identifies malignant melanoma, basal cell carcinoma, and squamous cell carcinoma, as well as benign tumors such as nevi, seborrheic keratoses, actinic keratoses, age spots, and lichen planus.
LifeSemantics aims to verify the safety, efficacy, and usability of Canofy MD SCAI in six medical institutions that include primary clinics and tertiary hospitals.
Matt is an award-winning storyteller, writer, and communicator currently based in Riyadh.
A native Englishman, his career has led him to diverse locations including China, Hong Kong, Iraq, Malaysia, Saudi Arabia, and the UAE.
In addition to founding HealthTechAsia, Matt is a co-founder of the non-profit Pul Alliance for Digital Health and Equity.
In a former life, he oversaw editorial coverage for Arab Health, Asia Health, Africa Health, and other key events.
In 2021, he won a Medical Travel Media Award, organised by Malaysia Healthcare Travel Council, and a Guardian Student Media Award in 2000.
Matt is an award-winning storyteller, writer, and communicator currently based in Riyadh.
A native Englishman, his career has led him to diverse locations including China, Hong Kong, Iraq, Malaysia, Saudi Arabia, and the UAE.
In addition to founding HealthTechAsia, Matt is a co-founder of the non-profit Pul Alliance for Digital Health and Equity.
In a former life, he oversaw editorial coverage for Arab Health, Asia Health, Africa Health, and other key events.
In 2021, he won a Medical Travel Media Award, organised by Malaysia Healthcare Travel Council, and a Guardian Student Media Award in 2000.
By Matthew Brady 
